1. Home
  2. DKL vs SUPN Comparison

DKL vs SUPN Comparison

Compare DKL & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKL

Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

HOLD

Current Price

$45.82

Market Cap

2.4B

Sector

Energy

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$45.68

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKL
SUPN
Founded
2012
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.6B
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
DKL
SUPN
Price
$45.82
$45.68
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$45.50
$63.25
AVG Volume (30 Days)
63.1K
782.6K
Earning Date
11-07-2025
11-04-2025
Dividend Yield
9.78%
N/A
EPS Growth
9.17
N/A
EPS
3.09
N/A
Revenue
$967,420,000.00
$681,539,000.00
Revenue This Year
$12.80
$8.32
Revenue Next Year
$11.50
$23.36
P/E Ratio
$14.82
N/A
Revenue Growth
N/A
4.54
52 Week Low
$34.59
$29.16
52 Week High
$48.00
$57.65

Technical Indicators

Market Signals
Indicator
DKL
SUPN
Relative Strength Index (RSI) 55.62 46.31
Support Level $45.10 $44.09
Resistance Level $46.93 $47.00
Average True Range (ATR) 1.10 1.25
MACD 0.08 0.10
Stochastic Oscillator 72.16 57.97

Price Performance

Historical Comparison
DKL
SUPN

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: